Abbott wins FDA approval of Eterna spinal cord stimulation system Thermo Fisher Scientific introduces all-in-one AAV production system

USA – Abbott Laboratories has received FDA approval for its Eterna spinal cord stimulation (SCS) system for chronic pain management. The Eterna SCS system is the smallest implantable, rechargeable system currently available for this indication on the market. Abbott claims that it was created after extensive research with patients, physicians, and caregivers to better understand the unmet needs of chronic pain patients.

SCS technology reduces pain by

23% more than traditional waveform technology approaches. It improves the patient charging experience by requiring as few as five recharges per year when used in conjunction with a wireless charger. To provide superior pain relief, Eterna SCS employs the company’s proprietary low-dose BurstDR stimulation, which mimics natural firing patterns in the brain. Eterna also employs Abbott’s TotalScan MRI technology, which allows for fullbody MRI scans — a critical need for chronic pain patients who require access to advanced diagnostics and healthcare.

The system is anticipated to provide laboratories performing highly sensitive and precise DNA and RNA analysis with flexibility through three unique reaction plates. In addition, the regulatory decision is expected to strengthen Abbott’s Established Pharmaceuticals Division (EPD).